Christopher Dakhil, MD
Basic profileChristopher Dakhil is an Oncology physician affiliated with Cancer Center of Kansas. OpenAlex indexes 33 publications with 590 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingIndustry payments
98 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Geron CorporationProgram year20254 payments$813
- Daiichi Sankyo Inc.Program year20256 payments$561
- Novartis Pharmaceuticals CorporationProgram year202518 payments$315
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
46.6%PD-1 inhibitor26.9%Pembrolizumab53%Nivolumab43%Atezolizumab4%Part B, office-administered≥53 patientsPlatinum-based Drug7.6%Oxaliplatin96%Carboplatin2%Cisplatin2%Part B, office-administered≥31 patients+ 14 more classes in this area
Metabolism & gastrointestinal
20.8%Substance P/Neurokinin-1 Receptor Antagonist11.3%Aprepitant100%Part B, office-administered≥91 patientsSerotonin-3 Receptor Antagonist9.2%Granisetron81%Ondansetron hydrochloride16%Palonosetron hcl3%Ondansetron Hcl0%Ondansetron Odt0%Part D + Part B<11 patients+ 4 more classes in this area
Blood & clotting
20.6%Iron, parenteral preparations15.6%Ferric carboxymaltose100%Part B, office-administered≥35 patientsErythropoiesis-stimulating Agent5%Darbepoetin alfa75%Epoetin alfa25%Part B, office-administered≥29 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Shaker Dakhil, MD
Cancer Center of Kansas
Bassam Mattar, MD
Cancer Center of Kansas
Jeremy Deutsch, MD
Cancer Center of Kansas
Dennis Moore, MD
Cancer Center of Kansas
Carl June, MD
University of Pennsylvania
Stuart Orkin, MD
Harvard Medical School
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”